Table 1 Pathways with significantly lower gene mutations in NSAID users
From: NSAID use and somatic exomic mutations in Barrett’s esophagus
Pathway | Functional mutations in pathway per NSAID user (mean (SEM)) | Functional mutations in pathway per NSAID non-user (mean (SEM)) | Mutation reduction in NSAID users (%) | p value |
|---|---|---|---|---|
DNA repair | 0.83 (0.18) | 1.71 (0.24) | − 51.43 | 0.003 |
Apoptosis | 1.00 (0.23) | 1.76 (0.25) | − 43.06 | 0.004 |
Caspase cascade in apoptosis | 0.17 (0.09) | 0.44 (0.09) | − 61.11 | 0.004 |
IFN-gamma pathway | 0.15 (0.06) | 0.56 (0.13) | − 73.91 | 0.005 |
Cellular response to stress | 1.41 (0.25) | 2.46 (0.33) | − 42.57 | 0.009 |
Cell cycle | 2.39 (0.33) | 4.20 (0.64) | − 43.02 | 0.014 |
p53 pathway | 0.51 (0.13) | 0.88 (0.15) | − 41.67 | 0.019 |
VEGFR1 specific signals | 0.15 (0.06) | 0.39 (0.09) | − 62.5 | 0.035 |
DNA replication/Mitotic M-MG1 phases | 2.12 (0.31) | 3.37 (0.48) | − 36.96 | 0.042 |